文献速递类风湿关节炎

类风湿关节炎患者全髋或全膝关节置换术后翻修、假体周围感染和死亡的预测因素:基于丹麦医疗登记系统的全国性队列研究

Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers.
PubMed 文献 · Ann Rheum Dis · 2017-11-02

基于丹麦全国登记系统的队列研究,比较3913例类风湿关节炎(RA)与120499例骨关节炎(OA)患者全髋/全膝关节置换术后的结局。RA患者翻修风险降低(SHR 0.71),但假体周围感染(SHR 1.46)和死亡(HR 1.25)风险增加。术前90天内使用生物改善病情抗风湿药(bDMARD)与翻修、感染或死亡风险无统计学显著增加相关;糖皮质激素暴露和DAS28升高是死亡危险因素。

要点

  • RA患者全髋/全膝关节置换术后10年翻修风险低于OA患者(SHR 0.71),但假体周围感染和死亡风险增加。
  • 术前90天内使用bDMARD与翻修、假体周围感染或死亡风险无统计学显著增加相关。
  • 糖皮质激素暴露(HR 2.87)和DAS28升高(HR 1.49)是RA患者术后死亡的危险因素。

核心结论

  • 与OA患者相比,RA患者全髋/全膝关节置换术后10年翻修风险降低,而死亡和假体周围感染风险增加。
  • 本研究中bDMARD暴露与假体周围感染或死亡风险无统计学显著增加相关。
  • 糖皮质激素暴露和疾病活动度升高与死亡风险增加相关。

研究设计与样本

  • 基于登记系统的队列研究,使用丹麦国家患者登记系统、DANBIO风湿病登记系统(RA特异性混杂因素和治疗 episode)以及丹麦髋关节和膝关节置换登记系统。
  • 共纳入3913例接受全髋/全膝关节置换的RA患者,与120499例接受同类手术的OA患者进行比较。
  • 在DANBIO中,1946例接受全髋/全膝关节置换的RA患者中有345例在术前90天内接受过bDMARD治疗。
  • 采用生存分析计算经混杂因素校正的亚风险比(SHR)和风险比(HR)。

主要发现

  • RA患者与OA患者相比:翻修风险降低(SHR 0.71(0.57-0.89)),假体周围感染风险增加(SHR 1.46(1.13-1.88)),死亡风险增加(HR 1.25(1.01-1.55))。
  • bDMARD治疗患者与非治疗患者相比:翻修风险无统计学显著增加(SHR 1.49(0.65-3.40)),假体周围感染风险无统计学显著增加(SHR 1.61(0.70-3.69)),死亡风险无统计学显著增加(HR 0.75(0.24-2.33))。
  • 糖皮质激素暴露是死亡的危险因素(HR 2.87(1.12-7.34))。
  • DAS28升高是死亡的危险因素(HR 1.49(1.01-2.20))。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate predictors of 10-year risk of revision and 1-year risk of prosthetic joint infection (PJI) and death following total hip/total knee arthroplasty (THA/TKA) in (1) patients with rheumatoid arthritis (RA) compared with patients with osteoarthritis (OA); and (2) patients with RA treated with biological disease-modifying antirheumatic drugs (bDMARD) within 90 days preceding surgery compared with non-treated. METHODS: Register-based cohort study using the Danish National Patient Register, the DANBIO rheumatology register (RA-specific confounders and treatment episodes) and the Danish Hip and Knee Arthroplasty Registers. Survival analyses were used to calculate confounder-adjusted sub-HRs (SHR) and HRs. RESULTS: In total, 3913 patients with RA with THA/TKA were compared with 120 499 patients with OA. Patients with RA had decreased risk of revision (SHR 0.71 (0.57-0.89)), but increased risk of PJI (SHR=1.46 (1.13-1.88)) and death (HR=1.25 (1.01-1.55)). In DANBIO, 345 of 1946 patients with RA with THA/TKA had received bDMARD treatment within 90 days preceding surgery. bDMARD-treated patients did not have a statistically significant increased risk of revision (SHR=1.49 (0.65-3.40)), PJI (SHR=1.61 (0.70-3.69)) nor death (HR=0.75 (0.24-2.33)) compared with non-treated. Glucocorticoid exposure (HR=2.87 (1.12-7.34)) and increasing DAS28 (HR=1.49 (1.01-2.20)) were risk factors for mortality. CONCLUSION: Patients with RA had a decreased 10-year risk of revision while the risk of death and PJI was increased compared with patients with OA following THA/TKA. bDMARD exposure was not associated with statistically significant increased risk of neither PJI nor death in this study. Glucocorticoid exposure and increased disease activity were associated with an increased risk of death.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Cordtz RL, Zobbe K, Højgaard P, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers. Ann Rheum Dis. 2017. PMID: 29097373. doi:10.1136/annrheumdis-2017-212339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。